

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

CLARIFICATION ANNOUNCEMENT IN RELATION TO INSIDE INFORMATION DISPOSAL OF SHARES BY SUBSTANTIAL SHAREHOLDER

Reference is made to the announcement of Lee's Pharmaceutical Holdings Limited (the "**Company**") dated 3 April 2017 in relation to the disposal of shares of the Company by a substantial shareholder of the Company (the "**Announcement**"). Unless otherwise defined, capitalized terms used in this announcement have the same meanings as those defined in the Announcement.

The Company is aware of an inadvertent mistake in the Announcement and wishes to clarify that the total investment in the Fund held by Dr. Li Xiaoyi as limited partner is approximately 5.56% instead of 5.71%.

Save for the aforesaid, all the information in the Announcement remains unchanged.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board of
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 6 April 2017

* *For identification purpose only*

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors, Dr. Marco Maria Brughera is a non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.